Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, venous thrombosis and an association with aplastic anemia 1 Among the many proteins missing from the surface of PNH cells are the complement regulatory proteins CD55 (Decay Accelerating Factor) and CD59 (also known as protectin and Membrane Inhibitor of Reactive Lysis) [6] [7] [8] . The increased complement sensitivity of PNH cells leads to hemolysis and thrombosis 9 . CD55 inhibits C3 and C5
convertases, whereas CD59 is the sole membrane regulator of membrane attack
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From complex (MAC) assembly. As there are additional inhibitors of C3 convertases in human plasma, bystander activation of complement is suppressed even in the absence of CD55. Inherited deficiencies of CD55 (Inab phenotype) are not associated with the symptoms of PNH indicating that loss of CD55 is not responsible for the hemolysis in PNH [10] [11] [12] . In contrast, inherited CD59 deficiency results in intravascular hemolysis, hemoglobinuria and other features indistinguishable from PNH 13, 14 . As a result of complement-mediated attack, the survival of PNH erythrocytes in vivo is shortened to about 10% that of normal erythrocytes. Patients with only partially deficient (Type II) PNH cells do not suffer from significant hemolysis indicating that low levels of CD59 are sufficient to control terminal complement activity.
The platelets in PNH patients also lack GPI-anchored proteins. Another approach to the prevention of hemolysis in PNH is to restore CD59 onto the surface of PNH erythrocytes. This should prevent complement-mediated hemolysis and the generation of procoagulant microparticles from platelets while leaving the anti-infective potential of C3 and C5 activation products unaffected. There are a number of practical difficulties associated with using CD59 in its natural GPIanchored form as a therapeutic agent (see Discussion). rhCD59-P is a recombinant human soluble CD59 expressed in E. coli, which has been modified using a Cterminal site-specific attachment of a soluble membrane-interactive peptide to replace the GPI anchor of endogenous CD59 (Prodaptin TM technology - Figure 1 ). The modification enables exogenously administered proteins to bind to the cell membrane in an analogous manner to GPI-anchors. A related form of Prodaptin modification has been used previously to localize other complement inhibitors to disease sites in animal models and has been progressed to clinical studies [20] [21] [22] [23] . Here we report the use of this technology in a new form to enable CD59 replacement therapy in PNH.
Methods

Protein agents
rhCD59 was prepared by expression in E. coli of a synthetic gene encoding residues 1-77 of native human CD59 with a C-terminal cysteine residue and refolded from inclusion bodies. The product was reacted with the bis-myristoylated modifying agent
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From APT3146 and purified to give rhCD59-P as a ~ 9kDa protein. APT3146 was prepared using conventional peptide synthesis to assemble a sequence KSSKSPSKKDDKKPGDC in which the protecting group strategy enabled both amino groups on the N-terminal lysine to be deprotected and then subjected to Nmyristoylation independently of the other lysines. The final thiol-reactive reagent was prepared by reacting the fully deprotected soluble myristoylated peptide with 2,2' dithiopyridine to yield a C-terminal mixed disulfide. Further details of the design of APT3146 and preparation of rhCD59-P will be presented elsewhere (D. Esser et al, in preparation). In order to establish the range of concentrations over which CD59 was detectable on the surface of the erythrocytes after incubation with rhCD59-P, we repeated the first experiment using blood from 6 patients and incubating with rhCD59-P alone at doubling dilutions from 15500nM to 15nM. Two-color flow cytometry, with antiFor personal use only. on July 16, 2017. by guest www.bloodjournal.org From CD59-FITC and anti-CD55-PE (Chemicon, Chandler's Ford, Hampshire, UK), was used to ensure that erythrocytes were not hemolysed after incubation with high concentrations of rhCD59-P.
Using 1000nM rhCD59-P, we incubated whole blood from patients with PNH for time periods from 1 minute to 4 hours to establish the rate at which the compound bound to PNH erythrocytes. In order to define the duration of efficacy erythrocytes bound with rhCD59-P after 30 minutes incubation were maintained for 1 to 7 days at 37°C and at 4°C and were analyzed at regular intervals. In addition, rhCD59-P bound erythrocytes were stored in either patient's plasma or patient's plasma plus 1000nM rhCD59-P and were analyzed with two-color flow cytometry using anti-CD59-FITC and anti-CD235a-PE. The samples stored in patient's plasma plus 1000nM rhCD59-P were additionally analyzed by flow cytometry after washing twice with PBS before the addition of the antibody solution.
In order to assess whether rhCD59-P transferred to cells after the initial binding, whole PNH blood (taken from patients with a large PNH clone) was incubated with 1850nM rhCD59-P at 37ºC for 30 minutes followed by a PBS wash producing reconstituted cells. Whole PNH blood (at neat, 1/10 and 1/100 concentrations, using PBS as the diluent) and washed PNH blood cells (at neat, 1/10 and 1/100 concentrations, using PBS as the diluent), with or without plasma, were then added to the reconstituted cells. These were incubated at 37ºC and samples taken at several time points between 1 minute and 72 hours and analyzed by flow cytometry as described above. In a separate experiment to assess whether rhCD59-P was transferred to the supernatant and retained the ability to bind to untreated PNH cells, PNH whole blood was incubated with 1850nM rhCD59-P at 37ºC for 30 minutes, following which the cells were washed and 200µl PBS added. The cells were centrifuged at 2000rpm for 1 minute and the supernatant was added to untreated whole PNH blood (neat and 1/10 concentration diluted in PBS). This was incubated at 37ºC for 30 minutes and then analyzed by flow cytometry as described above.
In vivo experiments
In order to assess the use of rhCD59-P in vivo, adult female CD1 mice (three per group) were administered by tail vein injection either vehicle, rhCD59, or rhCD59-P (each at 10mg/kg or 50mg/kg and at a volume of 10ml/kg). Blood samples (50-100μl) were obtained from tail bleeds into ACD at 15 minutes, 1 hour, 3 hours, 6 hours and 24 hours, when the mice were terminated. Blood was centrifuged and plasma removed for analysis. The mouse erythrocytes were then subjected to a human complement challenge using diluted serum which resulted in hemolysis (mediated by the alternative pathway; data not shown). Erythrocyte pellets were washed once with PBS/0.1% (w/v) gelatin and reconstituted to an average of ~25% hematocrit with PBS/gelatin. 5μl erythrocytes were mixed with either 45μl normal human AB serum The values from compound-treated mice were then expressed as % hemolysis relative to the corresponding 100% value. The experiment was repeated with two groups of five CD1 mice injected with either vehicle or 50mg/kg rhCD59-P. Time points for blood sampling were 3 hours, 24 hours and 48 hours.
In a separate experiment, two groups of CD1 mice (three per group) were injected with either vehicle or 10mg/kg rhCD59-P. Samples were taken at 1 hour, 4 hours, 24 hours and 48 hours. The amount of CD59 coating the erythrocytes was assessed by flow cytometry as described above. Each sample was analyzed in triplicate. As a control, mouse erythrocytes were incubated in vitro with doubling dilutions of rhCD59-P from 6200nM to 775nM as standards, at each time point. Additional in vitro controls included PBS with mouse erythrocytes as a negative control, PBS with human erythrocytes from a normal volunteer and PBS with human erythrocytes from a patient with PNH. These samples were run in duplicate. Hemolytic assays were repeated in parallel.
Results
The in vitro activity of rhCD59-P against complement-mediated lysis of guinea pig erythrocytes correlates with cell binding
Cell binding activity was determined by in vitro immunofluorescence studies with guinea pig erythrocytes. Binding was demonstrated with rhCD59-P but there was no binding with rhCD59, the parent protein lacking the Prodaptin modification ( Fig. 2A) .
This binding correlated with activity in a 'reactive lysis' assay 24 in which guinea pig erythrocytes were subjected to the activated terminal pathway of human complement.
rhCD59-P was found to inhibit hemolysis with an IC 50 of approximately 0.2nM (Fig.   2B ). In contrast, rhCD59 was over 1,000-fold less active in this assay.
rhCD59-P protects PNH erythrocytes in the Ham assay
The Ham test has been widely used in the diagnosis of PNH and is a measure of hemolysis in the presence of acidified human serum 25 . rhCD59-P (but not rhCD59) strongly inhibited hemolysis of erythrocytes in this assay (Fig 2C) . rhCD59-P was protective in Ham's assays using erythrocytes from different PNH patients, with an average IC 50 of 150nM.
In vitro attachment of rhCD59-P to human PNH erythrocytes
The in vitro binding of rhCD59-P to PNH erythrocytes was investigated next for two reasons: firstly, to correlate levels of cell surface binding with levels of protection in the Ham assay and, secondly, to utilize the ability of flow cytometry to detect three discrete populations of PNH cells based upon surface levels of CD59.
Different concentrations of rhCD59-P were incubated with whole blood from 6 PNH patients and the levels of surface CD59 were compared with non-PNH human red cells analyzed concomitantly. Binding was shown to be dose-dependent with normal levels of CD59 on PNH erythrocytes being achieved at high concentrations of rhCD59-P (Fig. 3A-G) , effectively reversing the CD59 deficiency of the PNH phenotype. Levels of CD59 similar to that found on type II cells were achieved at concentrations of at least 100nM rhCD59-P in all patient blood samples but binding of rhCD59-P to erythrocytes was evident below 100nM. The compound also bound to
(data not shown). In contrast, no blood cell binding of unmodified rh-CD59 was detected when used at 1700nM (data not shown). Double fluorescent staining for CD55 and CD59 demonstrated that PNH erythrocytes were CD59 positive following incubation with rhCD59-P and remained CD55 negative. Binding onto PNH type III cells was rapid, and the CD59 remained bound on the erythrocytes after 3 days storage at either 4 C or 37 C (data not shown). The CD59 remained detectable, albeit reduced in amount, on the erythrocytes after 24 hours.
Transfer of rhCD59-P from reconstituted PNH cells to non-reconstituted PNH cells
To assess whether rhCD59-P could transfer from reconstituted PNH cells (after an initial incubation with 1850nM rhCD59-P) neat, 1/10 and 1/100 concentrations of whole and washed PNH blood cells were added to the reconstituted cells for different times between 1 min and 24 h. The results showed that there was transfer of the protein to the non-reconstituted added cells after incubation at 37ºC (Fig. 4) and that this transfer was rapid (occurring during the 1 min time point). Similar levels of coating were found after the addition of 1/10 and 1/100 whole and washed PNH blood cells. The cells remained maximally coated at 3.5h (data not shown), with a slight decrease by 24 hours (Fig. 4) . Adding neat whole PNH blood showed evidence of binding of the protein but at a reduced level compared to the 1/10 and 1/100 dilutions, with lower amounts still when neat washed PNH blood cells were added (data not shown). This may be due to high density lipoproteins acting as carriers of CD59 as reported by Vakeva et al 26 .
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Ability of supernatant from reconstituted PNH cells to transfer rhCD59-P to untreated PNH cells
To assess whether rhCD59-P was transferred to the supernatant and retained the ability to bind to untreated PNH cells, reconstituted PNH cells (after an initial incubation with 1850nM rhCD59-P) were washed and PBS added. After further centrifugation the supernatant was added to neat and 1/10 untreated whole PNH blood (i.e. non-reconstituted cells). There was increased binding of CD59 after the addition of 1/10 whole PNH blood. This demonstrates the ability of rhCD59-P to dissociate from the red cells into the surrounding fluid, which is then capable of correcting the CD59 deficiency of nearby cells.
Administration of rhCD59-P to CD1 mice results in erythrocyte binding and protection.
To assess whether the activities of rhCD59-P shown in vitro could be replicated in an in vivo setting, CD1 mice were injected with the agent and blood samples were taken at time points for analysis by flow cytometry and hemolytic assay.
Erythrocytes from mice after intravenous injection of 10mg/kg rhCD59-P had supranormal levels of CD59 relative to normal human cells at 1 hour post-injection, normal levels at 4 hours and levels equivalent to those found in patients with partially deficient (Type II) PNH erythrocytes at 24 hours with none being detectable at 48 hours ( Figure 5A-E) . Parallel hemolytic assays using human serum as a complement source revealed that erythrocytes from mice injected with 10mg/kg rhCD59-P were protected against lysis, at least in part, for up to the 24 hours in comparison with erythrocytes from vehicle-injected mice (Fig. 6A) . In a separate experiment, 50mg/kg For personal use only. on July 16, 2017. by guest www.bloodjournal.org From rhCD59-P afforded full protection against hemolysis at 24 hours (data not shown). In contrast, the control compound rhCD59 demonstrated no protection of erythrocytes at either 10mg/kg or 50mg/kg ( Figure 6B ). An ELISA-based comparison of the clearance of rhCD59-P and rhCD59 from the plasma fluid phase showed that the former was significantly more slowly eliminated (half-life ~ 3 hours versus < 1 hour for unmodified rh-CD59) (data not shown).
Discussion
The data presented provide a demonstration of the feasibility of CD59 replacement therapy in PNH. Theoretically, this could prevent the considerable morbidity associated with complement-mediated red cell lysis and thrombosis in this group of patients. This work has shown that a form of CD59 modified with a novel synthetic membrane-anchoring peptide efficiently attaches to the surface of PNH erythrocytes in vitro and can deliver CD59 to blood cells at levels which restore complement regulatory activity. It is recognized that even low levels of CD59 on erythrocyte membranes are sufficient to protect the cells from lysis in vitro.
In previous studies, truncated forms of CD59 lacking the GPI anchor have been shown to inhibit complement-mediated lysis of guinea pig erythrocytes in vitro, but with ~100-fold lower efficiency than the GPI protein. Soluble CD59 lacking the GPI anchor, such as that found in PNH patients, is rapidly removed from the circulation through the kidneys on account of its low molecular weight 27 . When isolated with their GPI anchors intact, GPI-linked proteins can readily re-insert into cell membranes and cell-to cell transfer of such proteins has been demonstrated [28] [29] [30] [31] [32] [33] [34] . PNH
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In the presence of serum, the ability of GPI-CD59 to re-insert into the cell membrane of guinea pig erythrocytes is greatly reduced or eliminated. It is likely that this is due to the adsorption of the protein onto serum albumin and/or lipoproteins via the GPI anchor. Thus, quite apart from the problems of large-scale manufacture of GPIanchored proteins, GPI-CD59 is unlikely to be useful for therapeutic purposes. Rother therapy with this molecule could provide a treatment for PNH patients 36 . However in view of the frequent co-existence of bone marrow failure in PNH it has proved extremely difficult to obtain hematopoietic stem cells for gene transfer studies 37 . Also, gene therapy still presents a number of, as yet, unresolved clinical challenges.
The activity of CD59 is subject to homologous restriction and murine CD59 cannot maximally regulate the activity of human complement. No complete animal model of PNH exists, although erythrocytes from transgenic mice mosaic for inactive PIG-A showed increased sensitivity to complement ex vivo 38 and knock-out mice lacking CD59 39 displayed some PNH pathology such as mild spontaneous intravascular hemolysis. rhCD59-P was not tested in CD59 -/-mice because human CD59 is significantly less active against rodent MAC than human 40 . Therefore we assessed the activity of rhCD59-P using ex vivo challenge of mouse erythrocytes with human serum as a source of complement, mediated by the alternative pathway. The data presented here are, to our knowledge, the first example of an exogenous CD59 being used in a whole animal to coat erythrocytes protecting them from human complementmediated attack. This provides a proof-of-concept for PNH and represents a potential novel therapeutic approach for patients with PNH, which does not block the terminal activation of complement and therefore would not carry the risks associated with general complement inhibition. The attachment of rhCD59-P to the red cell membrane was found to be very rapid and the interaction appears to be effective for at least 3 days in vitro. Adding PNH cells after the initial attachment of the protein demonstrated transfer or 'painting' onto the non-reconstituted cells suggesting that newly generated PNH cells would also be protected against complement mediated lysis. Intravenous injection of rhCD59-P effectively coats the erythrocytes of mice and protects them from lysis by human complement for at least 24 hours for as long as rhCD59-P remained in the circulation. The effective half-life may be longer in humans than in mice, given the generally slower clearance of plasma proteins in man.
Additionally, the question of immunogenicity will be addressed by studies with rat CD59-P in rats. Both issues will need to be addressed directly in Phase I clinical studies.
These studies demonstrate that this type of modification of proteins provides an effective method by which essentially any protein can be effectively localized on the surface of blood cells and they provide further evidence for the potentially wide applicability of this targeted approach. Unlike GPI-CD59, rhCD59-P can be made Whole PNH blood (A) was incubated with 1850nM rhCD59-P for 30 min at 37ºC, followed by a PBS wash to produce 'CD59-reconstituted' cells (B). A separate sample of PNH whole blood was diluted 1/100 in PBS and incubated in the presence of serum with the reconstituted cells at 37ºC for either 1 min (C) or 24 h (D). As a negative control, non-PNH human blood was incubated with 1/100-diluted PNH whole blood for 30 min at 37ºC (E). Surface levels of human CD59 were measured on all samples by flow cytometry using a fluorescent anti-CD59 antibody. 
Figure 5
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